About: A risk benefit assessment of drugs used in the treatment of endometriosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A risk benefit assessment of drugs used in the treatment of endometriosis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 August 1994

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 1994 (uk) article scientifique publié en 1994 (fr) im August 1994 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'agostu de 1994 (ast) scientific article published on 01 August 1994 (en)
publication date	wds:Q72768863-F31427C5-5026-4F79-B6D7-DA3B35E2A1FC
publication date	1994-08-01 00:00:00Z (xsd:dateTime)
exact match	wds:Q72768863-8BE73895-DB39-4453-B9D7-69A4BAB7EBEE
exact match	https://scigraph.springernature.com/pub.10.2165/00002018-199411020-00005
cites work	wds:Q72768863-0F3EF8A6-9FE0-47D0-A24A-E0C19CD2D5B1 wds:Q72768863-128EDF08-B081-4D3F-ABB4-DF1CF3546FB9 wds:Q72768863-13C4B754-01C4-4E3B-BD3D-EF2D5F7097EB wds:Q72768863-1973A029-173D-458F-A19D-D19F57AC5A14 wds:Q72768863-1BEC855C-5F6E-4C24-9983-1C5D747CA0F1 wds:Q72768863-1F744C2C-5A83-4C73-887B-889CD71CF6EE wds:Q72768863-25E35826-C87D-4FE9-8C8C-758A9B5A1CE0 wds:Q72768863-45F49EC1-AEE2-4A04-B72A-69FB082FB496 wds:Q72768863-47FFF402-70D2-443A-9A57-C5E621D9F1E2 wds:Q72768863-504BFF9C-3350-4688-B31C-183EDF8F7A52 wds:Q72768863-551447B9-4D08-4437-9064-ECAABA04A2FA wds:Q72768863-68E7D62A-2343-4329-A1F9-850F727C6690 wds:Q72768863-88AB917F-81C9-45BE-ACB8-85131E037E2A wds:Q72768863-89F3AD92-5B1E-44AA-93F0-6C8F27A5E6B7 wds:Q72768863-8AE036B7-AB5C-47C9-9CF5-3D345938CE6A wds:Q72768863-92C7CB68-50C8-414E-AC36-DB955DE11A26 wds:Q72768863-A7752A90-5E4A-4C64-8026-24578F2704DB wds:Q72768863-AADAA2F0-5DD9-4C00-BBFA-735B1D81ADB8 wds:Q72768863-B0A71F1B-F4B4-4400-BF3C-AFE691A62B42 wds:Q72768863-B4749FB7-86E4-486D-87E3-0F467721F274 wds:Q72768863-B5984D55-A7B4-4531-8D7B-7D5BD07E84B2 wds:Q72768863-C175969C-C86E-4F9D-9DE9-877D477F035F wds:Q72768863-C4D1A58F-1777-4D73-909B-4247A10F7D79 wds:Q72768863-C8F9A08A-5636-4669-B86F-27C58BB19433 wds:Q72768863-CD436652-1255-4B79-B32B-DDFFAEED5E0D wds:Q72768863-CE19297E-D33E-4D1F-A0CA-6C23C5458AD9 wds:Q72768863-E420591A-9ABF-421C-88B3-207C7CE14531 wds:Q72768863-F972C81B-716C-47CA-BCAA-6D1DD12766DF
cites work	Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women Deficient cellular immunity in endometriosis Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team Treatment of endometriosis: a study of medical management. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis Gestrinone versus danazol in the treatment of endometriosis Revised American Fertility Society classification of endometriosis: 1985 Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET) The effects of lactation on bone mineral content in healthy postpartum women Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu)6 AZA Gly10 GnRH. Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol Endometriosis: treatment with hormonal pseudopregnancy and-or operation Ultrastructural comparison of endometriotic implants and eutopic endometrium Effects of danazol on pulsatile gonadotropin patterns and on serum estradiol levels in normally cycling women. Effect of gestrinone in endometriosis tissue and endometrium Evaluation of preoperative use of danazol, gestrinone, lynestrenol, buserelin spray and buserelin implant, in the treatment of endometriosis associated infertility Regression of endometriosis following shorter treatment with, or lower dose of danazol. Comparison of pre- and post-treatment laparoscopic findings in the Scandinavian multi-center study Prostaglandin biosynthesis inhibitors and endometriosis Treatment of endometriosis with an antigonadotropin, Danazol. A laparoscopic and histologic evaluation Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group Effects of nafarelin versus danazol on lipids and calcium metabolism Prostaglandins and Endometriosis A comparison of the efficacy and safety of buserelin vs danazol in the treatment of endometriosis. Protocol 310 Study Group Variable effects of danazol on endometriosis at 4 low-dose levels
author name string	wds:Q72768863-826E2223-6895-47D3-A2C2-6DFD01C029CC
author name string	R W Shaw
rdfs:label	A risk benefit assessment of drugs used in the treatment of endometriosis (en) A risk benefit assessment of drugs used in the treatment of endometriosis (nl)
skos:prefLabel	A risk benefit assessment of drugs used in the treatment of endometriosis (en) A risk benefit assessment of drugs used in the treatment of endometriosis (nl)
name	A risk benefit assessment of drugs used in the treatment of endometriosis (en) A risk benefit assessment of drugs used in the treatment of endometriosis (nl)
title	wds:Q72768863-36E43B37-5A54-4081-83E4-CBB2E440CF19
title	A risk benefit assessment of drugs used in the treatment of endometriosis (en)
page(s)	wds:Q72768863-EB25B829-E7BD-4F98-8E25-3070B29F9514
page(s)	104-113
instance of	wds:Q72768863-664f0e6b-ed3a-4801-81b9-21b806059579 wds:Q72768863-BB7D6EAC-196D-4B0D-9086-780F4BDC7F37
instance of	review article scholarly article
main subject	wds:Q72768863-67580193-BC6C-4C85-B52A-3A5CBAFC5C9B
main subject	endometriosis
PubMed ID	wds:Q72768863-F2A31111-FD90-4050-819A-04693BCE8A19
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7945998
PubMed ID	7945998
published in	wds:Q72768863-41B20744-EBED-4956-869C-5313A4BE2D9A
published in	Drug Safety
issue	wds:Q72768863-84EF69C3-756A-45DE-AAE0-41CAD203778E
volume	wds:Q72768863-5AF5280C-373C-4F12-BDA3-4BCC565A9C8D
issue	2
volume	11
DOI	wds:Q72768863-71D40BE4-8236-4DD5-914B-E70A2B712C8B
DOI	http://dx.doi.org/10.2165/00002018-199411020-00005
DOI	10.2165/00002018-199411020-00005
Dimensions Publication ID	wds:Q72768863-44CBC8B9-57A0-45FB-A33D-CAF9A29E6068
Dimensions Publication ID	1014479208
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72768863

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software